Skip to main content
. 2023 Jan 11;18(1):19. doi: 10.1007/s11657-023-01210-4

Fig. 3.

Fig. 3

Comorbidities and health care utilization factors associated with persistence after 2 years by treatment cohort among patients without malignancy at baseline initiating treatment in 2010–2016. Please note different scales on x-axis for Risedronate compared to the other three treatments. *CCI, Charlson comorbidity index. **COPD, chronic obstructive pulmonary disease